Daniel J. Drucker
Drucker, Daniel J., 19..-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 192810644 (Personal)
Permalink: http://viaf.org/viaf/192810644
Preferred Forms
-
100 0 _
‡a
Daniel J. Drucker
-
100 1 _
‡a
Drucker, Daniel J.,
‡d
19..-....
4xx's: Alternate Name Forms (11)
Works
| Title | Sources |
|---|---|
| Gut hormones |
|
| Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection |
|
| Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction |
|
| Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls |
|
| Incretin-based therapies: a clinical need filled by unique metabolic effects |
|
| Incretin-based therapies for type 2 diabetes mellitus |
|
| Incretin-based therapy and the quest for sustained improvements in β-cell health |
|
| Incretin receptor null mice reveal key role of GLP-1 but not GIP in pancreatic beta cell adaptation to pregnancy |
|
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes |
|
| Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice |
|
| iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy |
|
| Insulin action in the double incretin receptor knockout mouse |
|
| Insulin Secretion Depends on Intra-islet Glucagon Signaling |
|
| Integrating global proteomic and genomic expression profiles generated from islet alpha cells: opportunities and challenges to deriving reliable biological inferences. |
|
| Intensive insulin therapy in newly diagnosed type 2 diabetes. |
|
| Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. |
|
| International Union of Pharmacology. XXXV. The glucagon receptor family |
|
| Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion |
|
| Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in mice |
|
| Islet α cells and glucagon--critical regulators of energy homeostasis |
|
| Lipid raft-dependent glucagon-like peptide-2 receptor trafficking occurs independently of agonist-induced desensitization. |
|
| Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway. |
|
| Liraglutide. |
|
| Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor. |
|
| Loss of Glp2r signaling activates hepatic stellate cells and exacerbates diet-induced steatohepatitis in mice |
|
| Lymphocytic infiltration and immune activation in metallothionein promoter-exendin-4 (MT-Exendin) transgenic mice |
|
| Microbial modulation of energy availability in the colon regulates intestinal transit |
|
| Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice |
|
| Modulation of taste sensitivity by GLP-1 signaling in taste buds |
|
| The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. |
|
| N-glycan remodeling on glucagon receptor is an effector of nutrient sensing by the hexosamine biosynthesis pathway |
|
| Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice |
|
| Never Waste a Good Crisis: Confronting Reproducibility in Translational Research |
|
| Normalization of obesity-associated insulin resistance through immunotherapy |
|
| Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure |
|
| Oxyntomodulin increases intrinsic heart rate through the glucagon receptor |
|
| Oxyntomodulin regulates resetting of the liver circadian clock by food. |
|
| Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. |
|
| Parathyroid hormone-like peptide |
|
| The past 10 years-new hormones, new functions, new endocrine organs |
|
| Pax-6 activates endogenous proglucagon gene expression in the rodent gastrointestinal epithelium |
|
| Pdx-1 is not sufficient for repression of proglucagon gene transcription in islet or enteroendocrine cells |
|
| Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice |
|
| Phenotypic Characterization of MIP-CreERT1Lphi Mice With Transgene-Driven Islet Expression of Human Growth Hormone |
|
| Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice |
|
| Physiological roles of the GIP receptor in murine brown adipose tissue |
|
| Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. |
|
| Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans |
|
| Precision medicine in the management of type 2 diabetes. |
|
| Proglucagon-Derived Peptides, Glucose-Dependent Insulinotropic Polypeptide, and Dipeptidyl Peptidase-4-Mechanisms of Action in Adipose Tissue |
|
| Prolonged gastrointestinal transit in a patient with a glucagon-like peptide (GLP)-1- and -2-producing neuroendocrine tumor |
|
| The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential |
|
| Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel Batokine |
|
| A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents |
|
| Regulation of Peptide-YY Synthesis and Secretion in Fetal Rat Intestinal Cultures* |
|
| Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control |
|
| Revisiting the complexity of GLP-1 action-from sites of synthesis to receptor activation |
|
| The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. |
|
| Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing |
|
| Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy |
|
| The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice. |
|
| The safety of incretin-based therapies--review of the scientific evidence |
|
| Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury Independent from GLP1 Receptor Signaling. |
|
| Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. |
|
| A switch from prohormone convertase |
|
| Tales beyond the crypt: glucagon-like peptide-2 and cytoprotection in the intestinal mucosa |
|
| TCF1 links GIPR signaling to the control of beta cell function and survival. |
|
| Therapeutic approaches to preserve islet mass in type 2 diabetes |
|
| Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes |
|
| Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action |
|
| Transgenic mice in the study of endocrine systems |
|
| Treatment of type 2 diabetes with the designer cytokine IC7Fc |
|
| Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. |
|
| Unraveling the complexities of gut endocrinology |
|
| Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance |
|
| Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency |
|
| WDC15 Basic and Clinical Stream to offer extensive coverage on treatment advances |
|
| When Does Water Find the Shortest Path Downhill? The Geometry of Steepest Descent Curves |
|
| β-Cell Inactivation of Gpr119 Unmasks Incretin Dependence of GPR119-Mediated Glucoregulation |
|
